HHS Secretary Nominee Burwell Pledges To Promote Innovation At FDA
This article was originally published in The Tan Sheet
In an appearance before the Senate HELP committee, Sylvia Burwell addressed questions on accelerated drug approvals at FDA, the Independent Payment Advisory Board and metrics for enhancing development of new Medicare payment models.
You may also be interested in...
What's in – and what fell out of – the massive US stimulus package.
US House leadership's COVID-19 aid package focuses on cost sharing relief for patients to ensure access to treatments and vaccines for the virus. The Senate's legislative proposal tried to provide Medicare reimbursement incentives to providers to facilitate uptake, but some of those provisions were later dropped.
Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.